Skip to main content
ATOSSA THERAPEUTICS, INC. logo

ATOSSA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ATOS ISIN · US04962H5063 US Manufacturing
Open in API
Filings indexed 622 across all filing types
Latest filing 2017-03-21 Investor Presentation
Country US United States of America
Listing US ATOS

About ATOSSA THERAPEUTICS, INC.

https://atossatherapeutics.com/

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative medicines for areas of significant unmet medical need, with a primary focus on oncology. The company is dedicated to addressing the full continuum of breast cancer care. Its lead program is centered on (Z)-endoxifen, a proprietary and potent selective estrogen receptor modulator (SERM). Atossa is advancing (Z)-endoxifen through clinical development for multiple breast cancer indications, including metastatic disease, aiming to provide a therapeutic with a potentially improved efficacy and tolerability profile.

Recent filings

Filing Released Lang Actions
FWP
Investor Presentation Classification · 95% confidence The document is titled 'Issuer Free Writing Prospectus' and references a preliminary prospectus and registration statement number 333-216031. It contains detailed information about the company's drug development programs, clinical trials, market opportunities, management team, and financial highlights such as cash and debt levels. The document is a corporate presentation dated March 20, 2017, intended for investors and related to a securities offering. It is not a full financial report like an Annual Report or Interim Report, nor is it a regulatory filing or certification. The content aligns with an Investor Presentation (IP) as it focuses on company strategy, pipeline, market, and financial highlights for potential investors. The document length (9558 characters) supports it being a full presentation rather than a brief announcement or certification.
2017-03-21 English
S-1/A
Capital/Financing Update Classification · 95% confidence The document is titled as an "Amendment No. 2 to Form S-1 Registration Statement" filed with the SEC. Form S-1 is a registration statement used by companies planning an initial public offering (IPO) or other securities offering. The text includes details about the securities being registered, offering price, underwriting, risk factors, and other information typical of a prospectus for a public offering. It is not a financial report, earnings release, or management discussion, but rather a regulatory filing related to capital raising. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is lengthy (15,000 characters) and contains substantive information about the offering, not just an announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the best classification is CAP with high confidence.
2017-03-21 English
10-Q/A
Interim / Quarterly Report Q1 2016
2017-03-21 English
10-Q/A
Interim / Quarterly Report Q2 2016
2017-03-21 English
10-Q/A
Interim / Quarterly Report Q3 2016
2017-03-21 English
10-K/A
Annual Report FY 2016
2017-03-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.